Interplay Between Interleukin-6 and Glucagon in the Regulation of Human Amino Acid and Protein Homeostasis

Sponsor
University Hospital, Basel, Switzerland
Study ID
NCT06721910
Status
Completed

Conditions

  • Amino Acid Change
  • Glucagon Resistance
  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 50 Years
Healthy Volunteers
Accepted

Interventions

  • Tocilizumab — DRUG
    Blockade of the interleukin-6 receptor
  • Placebo — OTHER
    Infusion of 100 ml normal saline

Study Details

The goal of this proof-of-concept study is to learn if interleukin-6 changes the effect of glucagon in healthy volunteers. The main question it aims to answer is: Does IL-6 influence how effectively glucagon lowers the concentration of amino acids in blood? Researchers will compare the infusion of normal saline and a blocker of the receptor for interleukin-6 to see if blocking interluekin-6 changes how effectively glucagon lowers the concentration of amino acids in blood. Participants will be asked to * receive either an infusion of normal saline or the interleukin-6 receptor blocker * participate in a study visit three weeks later at which they will receive infusions of hormones and amino acids to mimic the concentrations of the hormones insulin and glucagon during fasting or fed conditions * labelled glucose, glycerol and amino acids will also be infused continuously to track the fate of these molecules * during the hormone infusions blood samples will be taken repeatedly

Key Dates

Start date
Jan 15, 2025
Status verified
Sep 2025
Primary completion
Sep 18, 2025
Completion
Sep 18, 2025

Study Design

Enrollment
26 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Placebo Comparator: Placebo
    Infusion of 100 ml normal saline
  • Active Comparator: IL-6R ab
    Infusion of tocilizumab, 8mg/kg body weight or max. 800mg in 100 ml normal saline

Primary Outcome Measure

Change in maximum glucagon-induced reduction in total plasma amino acid concentrations [ Time Frame: At visit 2 during high glucagon phase (80-120 minutes) ]

Related Studies